News coverage about Genomic Health (NASDAQ:GHDX) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genomic Health earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 44.4241109459272 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several equities research analysts recently commented on the company. Canaccord Genuity reissued a “buy” rating and issued a $42.00 price target on shares of Genomic Health in a research note on Tuesday, January 16th. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. JPMorgan Chase & Co. cut Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price target for the company. in a research note on Wednesday, December 13th. ValuEngine cut Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $32.33.
Shares of Genomic Health (NASDAQ GHDX) opened at $33.88 on Friday. The stock has a market capitalization of $1,178.52, a P/E ratio of -282.33 and a beta of 0.66. Genomic Health has a 12-month low of $26.37 and a 12-month high of $37.50.
In other Genomic Health news, insider James J. Vaughn sold 1,379 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kimberly J. Popovits sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $34.99, for a total value of $349,900.00. The disclosure for this sale can be found here. Insiders have sold 75,717 shares of company stock valued at $2,508,132 in the last ninety days. Company insiders own 46.20% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.